Metastatic Colorectal Cancer Clinical Trials

A listing of 18 Metastatic Colorectal Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Colorectal Cancer

1 - 12 of 18

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 18 active clinical trials seeking participants for Metastatic Colorectal Cancer research studies. The states with the highest number of trials for Metastatic Colorectal Cancer participants are California, Florida, Texas and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Clinical Study

Recruiting

We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.

Conditions:

Cough

Chronic Cough

Asthma

Allergic Asthma

Sinusitis

Learn More

Featured Trial

Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)

Recruiting

Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.

Conditions:

Obsessive-Compulsive Disorder

Obsessive Compulsive Disorder

Obsessive Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder (OCD)

Obsessive-compulsive Disorders and Symptoms

Learn More

Featured Trial

High Triglyceride Clinical Research Study

Recruiting

Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.

Conditions:

High Triglycerides

High Triglyceride Level

Hypertriglyceridemia

Elevated Triglycerides

Triglycerides High

Learn More

A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer

NCT06614192

Recruiting

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused ABBV-400 to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). ABBV-400 is an investigational drug being developed for the treatment of CRC. Participants are put int... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: City of Hope National Medical Center /ID# 267875, Duarte, California +25 locations

City of Hope National Medical Center /ID# 267875, Duarte, California

City of Hope Orange County Lennar Foundation Cancer Center /ID# 270655, Irvine, California

USC Norris Comprehensive Cancer Center /ID# 268131, Los Angeles, California

Lutheran Medical Center- Cancer Centers of Colorado /ID# 268175, Golden, Colorado

Yale New Haven Hospital /ID# 269125, New Haven, Connecticut

St. Luke's Cancer Institute: Boise /ID# 268095, Boise, Idaho

Northwestern University Robert H. Lurie Comprehensive Cancer Center /ID# 268610, Chicago, Illinois

Hope And Healing Cancer Services /ID# 268541, Hinsdale, Illinois

Springfield Clinic /ID# 268666, Springfield, Illinois

Hattiesburg Clinic /ID# 267860, Hattiesburg, Mississippi

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 268185, Billings, Montana

Rutgers Cancer Institute of New Jersey /ID# 268056, New Brunswick, New Jersey

West Cancer Center and Research Institute - Germantown /ID# 268619, Germantown, Tennessee

Millennium Research & Clinical Development /ID# 268400, Houston, Texas

The Chaim Sheba Medical Center /ID# 267741, Ramat Gan, Tel-Aviv

Tel Aviv Sourasky Medical Center /ID# 267578, Tel Aviv, Tel-Aviv

Rambam Health Care Campus /ID# 267739, Haifa, Not set

Hadassah Medical Center-Hebrew University /ID# 267579, Jerusalem, Not set

Rabin Medical Center /ID# 267740, Petah Tikva, Not set

Assuta Medical Center /ID# 267745, Tel Aviv, Not set

Seoul National University Hospital /ID# 268719, Seoul, Seoul Teugbyeolsi

Asan Medical Center /ID# 268717, Seoul, Seoul Teugbyeolsi

Samsung Medical Center /ID# 268720, Seoul, Seoul Teugbyeolsi

Pan American Center for Oncology Trials /ID# 267888, Rio Piedras, Not set

China Medical University Hospital /ID# 267631, Taichung, Not set

Taipei Veterans General Hospital /ID# 267628, Taipei City, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT06149481

Recruiting

Background: Each year, more than 32,000 people in the United States are diagnosed with colorectal cancer that has returned or progressed after treatment and spread to other organs. This is called metastatic colorectal cancer (mCRC). Most people with mCRC survive only about 2 years. Objective: To test the ability of a combination of up to 4 experimental anti-cancer drugs treat mCRC. The names of these drugs are retifanlimab, TriAdeno vaccine, N-803, and SX-682. They are described below. Eligi... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

01/31/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Metastatic Colorectal Cancer

Learn More ›

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT01174121

Recruiting

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma. Researchers want to know if TIL shrink s tumors in people with digestive tract, urothelial, breast, or ovarian/endometrial cancers. In this study, we are selecting a specific subset of white blood cells from the tumor that we think are the most effective in fighting tumors and will use only these cells in making the tumor fighting cells. Objective: The purpose of this study is to see if these specifically selected tumor fighting cells can cause digestive tract, urothelial, breast, or ovarian/endometrial tumors to shrink and to see if this treatment is safe. Eligibility: - Adults age 18-72 with upper or lower gastrointestinal, hepatobiliary, genitourinary, breast, ovarian/endometrial cancer, or glioblastoma refractory to standard chemotherapy. Design: Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed. Surgery: If the patients meet all of the requirements for the study they will undergo surgery to remove a tumor that can be used to grow the TIL product. Leukapheresis: Patients may undergo leukapheresis to obtain additional white blood cells. (Leukapheresis is a common procedure, which removes only the white blood cells from the patient.) Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the TIL cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment. Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits will take up to 2 days. Read Less

Gender:

ALL

Ages:

Between 18 years and 72 years

Trial Updated:

01/31/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors

Learn More ›

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526

Recruiting

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/30/2025

Locations: Highlands Oncology Group, Springdale, Arkansas +36 locations

Highlands Oncology Group, Springdale, Arkansas

University of California at Davis, Davis, California

The Oncology Institute of Hope and Innovation, Downey, California

City of Hope Cancer Center, Duarte, California

University of Colorado Hospital, Aurora, Colorado

Nuvance Health, Norwalk, Connecticut

MedStar Georgetown University Hospital, Washington, District of Columbia

Florida Cancer Specialists, Atlantis, Florida

University of Florida Health Cancer Center, Gainesville, Florida

Ocala Oncology Florida Cancer Affiliates, Ocala, Florida

AdventHealth Cancer Institute, Orlando, Florida

Memorial Cancer Institute, Pembroke Pines, Florida

Emory University Winship Cancer Institute, Atlanta, Georgia

Norton Health, Lexington, Kentucky

Greater Baltimore Medical Center, Baltimore, Maryland

The Center for Cancer and Blood Disorders, Bethesda, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

University of Michigan Medical Center, Ann Arbor, Michigan

Atlantic Healthcare System, Morristown, New Jersey

Memorial Sloan Kettering Cancer Center, New York, New York

University of Cincinnati Medical Center, Cincinnati, Ohio

The Ohio State University James Cancer Center, Columbus, Ohio

Zangmeister Cancer Center, Columbus, Ohio

Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center), Gettysburg, Pennsylvania

Prisma Health, Greenville, South Carolina

Tennessee Oncology Chattanooga Memorial Plaza, Chattanooga, Tennessee

Tennessee Oncology - Nashville, Nashville, Tennessee

Houston Methodist Cancer Center, Houston, Texas

Oncology Consultants, Houston, Texas

University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

NEXT/Virginia Cancer Specialists, Fairfax, Virginia

University of Washington / Fred Hutchinson Cancer Center, Seattle, Washington

Newcastle Private Hospital, New Lambton Heights, New South Wales

Tasman Oncology Research, Southport, Queensland

Cancer Research SA, Adelaide, South Australia

Southern Oncology Clinical Research Unit, Bedford Park, South Australia

Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma

Learn More ›

Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)

NCT06625775

Recruiting

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: University of California Los Angeles, Los Angeles, California +5 locations

Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, HER2-Positive Advanced Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer

Learn More ›

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649

Recruiting

The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/22/2025

Locations: Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona +97 locations

Ironwood Cancer and Research Centers Scottsdale, Chandler, Arizona

Providence Saint Jude Medical Center, Fullerton, California

Cancer and Blood Specialty Clinic, Los Alamitos, California

Norwalk Hospital, Norwalk, Connecticut

Cancer Specialists of North Florida, Jacksonville, Florida

D and H Cancer Research Center, Margate, Florida

Mid Florida Hematology and Oncology Centers PA, Orange City, Florida

Boca Raton Clinical Research Medical Center Inc, Plantation, Florida

Georgia Cancer Specialists, Atlanta, Georgia

Hope and Healing Cancer Services, Hinsdale, Illinois

Orchard Healthcare Research Inc, Skokie, Illinois

Pikeville Medical Center, Pikeville, Kentucky

Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan

Saint Louis Cancer Care West County, Bridgeton, Missouri

Minniti Center for Medical Oncology and Hematology, Mickleton, New Jersey

Duke Cancer Center, Durham, North Carolina

FirstHealth Cancer Center, Pinehurst, North Carolina

Thomas Jefferson University, Philadelphia, Pennsylvania

Carolina Blood and Cancer Care, Rock Hill, South Carolina

Hospital Universitario Fundacion Favaloro, Caba, Buenos Aires

Instituto Argentino de Diagnóstico y Tratamiento, Caba, Buenos Aires

Cemic, Ciudad Autonoma de Buenos Aires, Buenos Aires

Sanatorio Británico de Rosario, La Plata, Buenos Aires

Instituto de Investigaciones clinicas de Mar del Plata, Mar Del Plata, Buenos Aires

Sanatorio Allende, Cordoba, Córdoba

Clinica Universitaria Privada Reina Fabiola, Cordoba, Córdoba

Clinica Viedma, Viedma, Río Negro

Exelsus Oncologia Clinica, San Miguel de Tucuman, Tucuman

Hospital Britanico de Buenos Aires, Buenos Aires, Not set

Chris OBrien Lifehouse, Camperdown, New South Wales

Toowoomba Hospital, Toowoomba, Queensland

Flinders Medical Centre, Bedford Park, South Australia

The Queen Elizabeth Hospital, Woodville South, South Australia

Austin Health, Austin Hospital, Heidelberg, Victoria

Hospital Sirio Libanes, Brasilia, Distrito Federal

Hospital Evangelico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Espírito Santo

Vencer e Oncoclinica, Teresina, Piauí

Liga Norte-Riograndense Contra O Cancer, Natal, Rio Grande Do Norte

Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Rio Grande Do Sul

Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul

Associação Hospitalar Moinhos de Vento, Porto Alegre, Rio Grande Do Sul

Clinica de Neoplasias Litoral, Itajai, Santa Catarina

Fundacao Pio 12 Hospital de Amor de Barretos, Barretos, São Paulo

Oncoclinicas Belo Horizonte, Barretos, São Paulo

Fundacao Antonio Prudente AC Camargo Cancer Center, Sao Paulo, São Paulo

Oncologia Rede D Or, Sao Paulo, São Paulo

Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto, São Paulo

Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira Icesp, São Paulo, Not set

Instituto Brasileiro de Controle do Cancer Ibcc, São Paulo, Not set

Institucion Prestadora de Servicios de Salud Sociedad Médica Rionegro SA Somer SA, Rionegro, Antioquia

Instituto Nacional de Cancerologia, Bogota, Cundinamarca

Centro de Tratamiento e Investigación sobre Cancer Luis Carlos Sarmiento Angulo Ctic, Bogotá, Cundinamarca

Fundacion Oftalmologica de Santander - Foscal, Floridablanca, Santander

Queen Mary Hospital, The University of Hong Kong, Hong Kong, Not set

Princess Margaret Hospital, Kowloon, Not set

Aichi Cancer Center, Nagoya-shi, Aichi

Chiba Cancer Center, Chiba-shi, Chiba

National Cancer Center Hospital East, Kashiwa-shi, Chiba

National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Ehime

National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Fukuoka

Hokkaido University Hospital, Sapporo, Hokkaido

Hyogo Cancer Center, Akashi-shi, Hyogo

St Marianna University Hospital, Kawasaki-shi, Kanagawa

Yokohama City University Medical Center, Yokohama-shi, Kanagawa

Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama-shi, Kanagawa

Niigata Cancer Center Hospital, Niigata-shi, Niigata

Kansai Medical University Hospital, Hirakata-shi, Osaka

National Hospital Organization Osaka National Hospital, Osaka-shi, Osaka

Osaka University Hospital, Suita-shi, Osaka

Saitama Cancer Center, Kitaadachi-gun, Saitama

Shizuoka Cancer Center, Sunto-gun, Shizuoka

Tokushima University Hospital, Tokushima-shi, Tokushima

National Cancer Center Hospital, Chuo-ku, Tokyo

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo

National Cancer Center, Goyang-si Gyeonggi-do, Not set

Korea University Anam Hospital, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Universitaetsspital Zuerich, Zuerich, Not set

China Medical University Hospital, Taichung, Not set

Taichung Veterans General Hospital, Taichung, Not set

Taipei Veterans General Hospital, Taipei, Not set

Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Not set

Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Not set

Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Not set

Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi, Ankara, Not set

Ankara Bilkent Sehir Hastanesi, Ankara, Not set

Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi, Edirne, Not set

Bezmialem Vakif Universitesi Hastanesi, Istanbul, Not set

Bagcilar Medipol Mega Universite Hastanesi, Istanbul, Not set

Acibadem Altunizade Hastanesi, Istanbul, Not set

Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Not set

Necmettin Erbakan Universitesi Tip Fakultesi Hastanesi, Konya, Not set

Inonu Universitesi Turgut Ozal Tip Merkezi, Malatya, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223

Recruiting

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/10/2025

Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +71 locations

UAB Comprehensive Cancer Center, Birmingham, Alabama

Mayo Clinic Arizona, Phoenix, Arizona

City of Hope Comprehensive Cancer Center, Duarte, California

cCare, Encinitas, California

USC Norris Cancer Center, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

UCLA, Los Angeles, California

Hoag Memorial Hospital Presbyterian, Newport Beach, California

Stanford Cancer Center, Stanford, California

University of Colorado Cancer Center, Aurora, Colorado

Yale Cancer Center, New Haven, Connecticut

Eastern Ct Hema/Onco Assoc, Norwich, Connecticut

Mayo Clinic in Florida, Jacksonville, Florida

Moffitt Cancer Center, Tampa, Florida

Mary Bird Perkins Cancer Ctr, Baton Rouge, Louisiana

Massachusetts General Hospital, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

New York Cancer & Blood Specialists - Bronx, Bronx, New York

New York Cancer & Blood Specialists - New Hyde Park, New Hyde Park, New York

New York Cancer and Blood Specialists-Central Park Hematology & Oncology, New York, New York

New York Cancer & Blood Specialists, Port Jefferson Station, New York

Duke University Medical Center, Durham, North Carolina

Hematology Oncology Salem, Salem, Oregon

UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania

Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Lumi Research, Kingwood, Texas

Swedish Cancer Inst., Seattle, Washington

Medical Oncology Associates, Spokane, Washington

Peter Maccallum Cancer Centre, Melbourne, Victoria

Princess Margaret Cancer Center, Toronto, Ontario

Jewish General Hospital, Montreal, Quebec

McGill University Health Center, Montreal, Quebec

Rigshospitalet, Onkologisk Klinik, København Ø, Not set

Charité Universitätsmedizin Berlin, Berlin, Not set

Katholisches Klinikum Bochum gGmbH - St. Josef-Hospital, Bochum, Not set

Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden, Dresden, Not set

Universitätsklinikum Düsseldorf, Düsseldorf, Not set

Asklepios Klinik Altona, Hamburg, Not set

SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III, Heilbronn, Not set

Klinikum der Universität München, Campus Großhadern, München, Not set

Universitätsklinikum Ulm, Ulm, Not set

Università degli Studi della Campania Luigi Vanvitelli, Napoli, Campania

Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio

Irccs Istituto Nazionale Dei Tumori (Int), Milano, Lombardia

Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milano, Lombardia

IRCCS Istituto Oncologico Veneto (IOV), Padova, Veneto

National Cancer Center, Goyang-si, Not set

Chonnam National University Hwasun Hospital, Jeollanam-do, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii, Kraków, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Not set

Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie, Warszawa, Not set

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Not set

START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Not set

START Madrid. Centro Integral Oncologico Clara Campal, Madrid, Not set

Hospital Clínico Universitario de Valencia, Valencia, Not set

National Cheng Kung University Hospital, Tainan, Not set

Taipei Veterans General Hospital, Taipei City, Not set

National Taiwan University Hospital, Zhongzheng Dist., Not set

Addenbrookes Hospital, Cambridge, Not set

Velindre Cancer Centre, Cardiff, Not set

Royal Free Hospital, London, Not set

Royal Marsden Hospital;Dept of Med-Onc, London, Not set

Sarah Cannon Research Institute, London, Not set

Imperial College Healthcare NHS Trust, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Royal Marsden Hospital, Sutton, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer

NCT05840263

Recruiting

The overall objective of this study is to develop a novel couple-based mindfulness intervention aimed at reducing distress in patients with metastatic colorectal cancer (mCRC) and their partners.

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

01/09/2025

Locations: University of Colorado Cancer Center, Aurora, Colorado

Conditions: Metastatic Colorectal Cancer

Learn More ›

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030

Recruiting

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR m... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/17/2024

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +173 locations

Banner MD Anderson Cancer Center, Gilbert, Arizona

Local Institution - 0059, Los Angeles, California

Local Institution - 0130, Sacramento, California

Local Institution - 0103, Denver, Colorado

Local Institution, Miami, Florida

Local Institution, Marietta, Georgia

Local Institution - 0119, Arlington Heights, Illinois

Local Institution - 0060, New York, New York

Local Institution - 0105, Portland, Oregon

Local Institution, Philadelphia, Pennsylvania

Local Institution - 0121, Pittsburgh, Pennsylvania

Local Institution - 0106, Dallas, Texas

Local Institution, Fort Worth, Texas

Local Institution - 0104, Roanoke, Virginia

Local Institution - 0073, Ciudad Autonoma Beunos Aires, Buenos Aires

Local Institution - 0074, Viedma, RIO Negro

Local Institution - 0084, Buenos Aires, Not set

Local Institution - 0100, Caba, Not set

Local Institution - 0072, Caba, Not set

Local Institution - 0019, Westmead, New South Wales

Local Institution - 0053, Woolloongabba, Queensland

Local Institution - 0018, Elizabeth Vale, South Australia

Local Institution - 0041, Clayton, Victoria

Local Institution - 0017, Heidelberg, Victoria

Local Institution - 0064, Graz, Not set

Local Institution - 0068, Linz, Not set

Local Institution - 0120, Salzburg, Not set

Local Institution - 0067, Wiener Neustadt, Not set

Local Institution - 0065, Wien, Not set

Local Institution - 0045, Bonheiden, Antwerpen

Local Institution - 0025, Anderlecht, Bruxelles-Capitale, Région De

Local Institution, Brussel, Not set

Local Institution - 0024, Leuven, Not set

Local Institution - 0096, Ipatinga, Minas Gerais

Local Institution - 0200, Natal, RIO Grande DO Norte

Local Institution - 0097, Porto Alegre, Rio Grande Do Sul

Local Institution - 0192, Porto Alegre, RIO Grande DO SUL

Local Institution - 0102, Barretos, Sao Paulo

Local Institution - 0095, Sao Paulo, São Paulo

Local Institution - 0094, São José do Rio Preto, São Paulo

Local Institution - 0199, Rio de Janeiro, Not set

Local Institution - 0193, São Paulo, Not set

Local Institution - 0011, Edmonton, Alberta

Local Institution - 0039, Vancouver, British Columbia

Local Institution, Halifax, Nova Scotia

Local Institution - 0013, Toronto, Ontario

Local Institution - 0016, Montreal, Quebec

Local Institution - 0015, Sherbrooke, Quebec

Local Institution, Quebec, Not set

Local Institution - 0071, Santiago, Metropolitana

Local Institution - 0069, Santiago, Metropolitana

Local Institution - 0070, Independencia, Santiago

Local Institution - 0146, Hefei, Anhui

Local Institution, Fuzhou, Fujian

The First Affiliated hospital of Xiamen University, Xiamen, Fujian

Zhangzhou Municipal Hospital of Fujian Province, Zhangzhou, Fujian

Lanzhou university second hospital, Lanzhou, Gansu

The First People's Hospital of Foshan, Foshan, Guangdong

Local Institution - 0194, Guangzhou, Guangdong

Local Institution - 0167, Guangzhou, Guangdong

Local Institution - 0153, Guangzhou, Guangdong

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong

The people's hospital of Guangxi Zhuang autonomous region, Nanning, Guangxi

Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan

Hunan Cancer Hospital, Changsha, Hunan

The First People's Hospital of Changzhou, Changzhou, Jiangsu

The 1st Affiliate Hospital Of Nanchang University, Nanchang, Jiangxi

The 1st Hospital Of Jilin University, Changchun, Jilin

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

Local Institution - 0188, Xi'an, Shaanxi

Shandong Cancer Hospital, Jinan, Shandong

Local Institution - 0212, Linyi, Shandong

Local Institution - 0154, Qingdao, Shandong

Local Institution - 0165, Yantai, Shandong

Local Institution - 0143, Shanghai, Shanghai

Shanghai East Hospital, Shanghai, Shanghai

Shanghai GoBroad Cancer Hospital China Pharmaceutical University, Shanghai, Shanghai

Yunnan Province Cancer Hospital, Kunming, Yunnan

The 2nd Affiliated Hospital Of Z.U.S.M, Hangzhou, Zhejiang

Local Institution - 0206, Ningbo, Zhejiang

Local Institution - 0087, Brno, Not set

Local Institution - 0085, Hradec Kralove, Not set

Local Institution - 0088, Novy Jicin, Not set

Local Institution - 0086, Olomouc, Not set

Local Institution - 0038, Herlev, Not set

Local Institution, Odense, Not set

Local Institution - 0036, Vejle, Not set

Local Institution - 0176, Limoges, Haute-Vienne

Local Institution - 0138, Lille, Nord

Local Institution - 0186, Bayonne, Not set

Local Institution - 0028, Besancon Cedex, Not set

Local Institution - 0029, Lyon Cedex 08, Not set

Local Institution - 0183, Lyon, Not set

Local Institution - 0066, Marseille, Not set

Local Institution - 0030, Montpellier, Not set

Local Institution - 0032, Nantes, Not set

Local Institution - 0027, Paris, Not set

Local Institution - 0061, Pessac Cedex, Not set

Local Institution - 0031, Poitiers, Not set

Local Institution, Rouen, Not set

Local Institution - 0184, Strasbourg, Not set

Local Institution - 0040, Toulouse, Not set

Local Institution - 0042, Dresden, Not set

Local Institution - 0007, Essen, Not set

Local Institution - 0043, Hamburg, Not set

Local Institution - 0117, Hamburg, Not set

Local Institution - 0008, Hannover, Not set

Local Institution - 0009, Heidelberg, Not set

Local Institution - 0044, Marburg, Not set

Local Institution - 0010, Munich, Not set

Local Institution - 0222, Athens, Attikí (Region)

Local Institution - 0123, Athens, Not set

Local Institution - 0125, Heraklion, Not set

Local Institution - 0124, Holargos, Not set

Local Institution - 0126, Ioannina, Not set

Local Institution - 0091, Dublin 8, Dublin

Local Institution - 0022, Dublin, Not set

Local Institution - 0026, Limerick, Not set

Local Institution - 0055, Catania, Not set

Local Institution - 0003, Genova, Not set

Local Institution - 0001, Milan, Not set

Local Institution - 0004, Napoli, Not set

Local Institution - 0002, Padova, Not set

Local Institution - 0054, Roma, Not set

Local Institution - 0109, Nagoya-shi, Aichi

Local Institution - 0112, Chiba-shi, Chiba

Local Institution - 0107, Kashiwa-shi, Chiba

Local Institution - 0132, Matsuyama, Ehime

Local Institution - 0116, Fukuoka-shi, Fukuoka

Local Institution - 0174, Sapporo-shi, Hokkaido

Local Institution - 0128, Kanazawa-city, Ishikawa

Local Institution - 0111, Kawasaki, Kanagawa

Local Institution - 0175, Yokohama, Kanagawa

Local Institution - 0133, Kumamoto-shi, Kumamoto

Local Institution - 0189, Osaki, Miyagi

Local Institution - 0177, Kurashiki, Okayama

Local Institution - 0115, Suita-shi, Osaka

Local Institution - 0187, Hidaka, Saitama

Local Institution - 0110, Kitaadachigun, Saitama

Local Institution - 0108, Sunto-gun, Shizuoka

Local Institution - 0118, Chuo-ku, Tokyo

Local Institution - 0113, Koto-ku, Tokyo

Local Institution - 0129, Minato-ku, Tokyo

Local Institution - 0114, Osaka, Not set

Local Institution - 0052, Amsterdam, Noord-Holland

Local Institution - 0051, Amsterdam, Noord-Holland

Local Institution - 0050, Utrecht, Not set

Local Institution - 0033, Bergen, Not set

Local Institution - 0034, Lorenskog, Not set

Local Institution - 0035, Oslo, Not set

Local Institution - 0058, Rio Piedras, Not set

Local Institution - 0076, Cluj-Napoca, Cluj

Local Institution - 0081, Craiova, Dolj

Local Institution - 0168, Brasov, Not set

Local Institution - 0080, Bucharest, Not set

Local Institution - 0075, Constanta, Not set

Local Institution - 0205, Iași, Not set

Local Institution - 0089, Suceava, Not set

Local Institution - 0056, Badalona, Barcelona [Barcelona]

Local Institution - 0173, A Coruna, Not set

Local Institution - 0006, Barcelona, Not set

Local Institution, Madrid, Not set

Local Institution - 0005, Madrid, Not set

Local Institution - 0172, Malaga, Not set

Local Institution - 0063, Sevilla, Not set

Local Institution - 0171, Valencia, Not set

Local Institution - 0092, Adana, Not set

Local Institution - 0101, Istanbul, Not set

Local Institution, London, Greater London

Local Institution, Leeds, Yorkshire

Local Institution - 0127, London, Not set

Local Institution - 0049, Oxford, Not set

Conditions: Metastatic Colorectal Cancer

Learn More ›

Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation

NCT06106308

Recruiting

The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/04/2024

Locations: Mayo Clinic - Arizona, Phoenix, Arizona +40 locations

Mayo Clinic - Arizona, Phoenix, Arizona

The University of Arizona Cancer Center, Tucson, Arizona

St. Bernards Medical Center, Jonesboro, Arkansas

Highlands Oncology Group, Springdale, Arkansas

Pacific Cancer Medical Center, Anaheim, California

Comprehensive Blood and Cancer Center - Bakersfield, Bakersfield, California

Orange Coast Memorial Medical Center, Fountain Valley, California

UC San Diego Moores Cancer Center, La Jolla, California

Norris Comprehensive Cancer Center, Los Angeles, California

UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California

Sharp Memorial Hospital, San Diego, California

Torrance Memorial Physician Network - Cancer Care and Infusion Center, Torrance, California

PIH Health, Whittier, California

Memorial Cancer Institute, Hollywood, Florida

Mayo Clinic - Florida, Jacksonville, Florida

Cleveland Clinic Martin Health, Stuart, Florida

Kaiser Permanente, Honolulu, Hawaii

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

The University of Kansas Cancer Center - Westwood, Westwood, Kansas

Cancer Center of Kansas, Wichita, Kansas

Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion, Grand Rapids, Michigan

Mayo Clinic Cancer Center, Rochester, Minnesota

Saint Luke's Hospital, Kansas City, Missouri

Washington University School of Medicine Center for Advanced Medicine, Saint Louis, Missouri

CCCN, Las Vegas, Nevada

Manhattan Hematology Oncology (MHO) Research Foundation, Inc., New York, New York

Trihealth Kenwood, Cincinnati, Ohio

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Cleveland Clinic, Cleveland, Ohio

The Ohio State University Wexner Medical Center, Columbus, Ohio

Oregon Health and Science University, Portland, Oregon

Lehigh Valley Health Network, Allentown, Pennsylvania

West Cancer Clinic, Germantown, Tennessee

Oncology Consultants, PA, Houston, Texas

MD Anderson Cancer Center, Houston, Texas

Utah Cancer Specialists, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Inova Schar Cancer Institute, Fairfax, Virginia

VCU Massey Cancer Center, Richmond, Virginia

Virginia Mason Medical Center, Seattle, Washington

ThedaCare Regional Cancer Center, Appleton, Wisconsin

Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation

Learn More ›

Pressure-enabled Delivery in Radioembolization (TriNav Study)

NCT05128032

Recruiting

The purpose of the study is to determine if the type of catheter used in the mapping procedure prior to radioembolization improves the delivery of radioactivity to tumor(s) in participants with liver cancer. The name of the devices involved in this study are: * Pressure Enabled Drug Delivery (PEDD)/TriNav Infusion System * Standard 2.4F microcatheter, not otherwise specified

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/18/2024

Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations

Conditions: Liver Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer

Learn More ›

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

NCT06412198

Recruiting

To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/13/2024

Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations

Conditions: Metastatic Colorectal Cancer, KRAS G12C Mutations

Learn More ›

1 - 12 of 18